Article

Fluorescein angiography, OCT both useful technologies in retinal disease management

Miami?Is it time to retire fluorescein angiography in light of the commercial availability of optical coherence tomography (OCT)? Certainly not, because they are complementary technologies that are integral to the management and treatment of retinal diseases, explained Carmen A. Puliafito, MD, MBA.

Miami-Is it time to retire fluorescein angiography in light of the commercial availability of optical coherence tomography (OCT)? Certainly not, because they are complementary technologies that are integral to the management and treatment of retinal diseases, explained Carmen A. Puliafito, MD, MBA.

"Both fluorescein angiography and OCT are necessary. Advances in therapy and technology, however, have altered the relative importance of both technologies in everyday life," Dr. Puliafito stated.

The reason clinicians still need both, he explained, is that fluorescein angiography may not be sufficient to pinpoint the problem. In assessing the vitreoretinal interface, OCT is superior to fluorescein angiography. This was the case of a patient who presented with a cataract and some macular degeneration. One month later, the patient was examined for a visual disturbance with only fluorescein angiography. If OCT had been done, the macular hole could have been identified immediately, said Dr. Puliafito. He is the Kathleen and Stanley Glaser Professor of Ophthalmology, Miller School of Medicine, University of Miami, and chair, Bascom Palmer Eye Institute, Miami.

A third patient with a visual acuity disturbance in the left eye was about to undergo a cataract extraction. The patient had focal vitreomacular traction, which was well documented on spectral OCT maps, which Dr. Puliafito demonstrated.

"The unique capabilities of fluorescein angiography are topographic localization, assessment of retinal capillary perfusion, and the potential usefulness of wide-field angiography," he said. Dr. Puliafito demonstrated how valuable fluorescein angiography is in showing the localization of neovascularization on the disc and elsewhere. A wide-field angiogram of a patient showed the evolution of the neovascularization and the extensive capillary nonperfusion. "The midperiphery remains an unknown in retinal vascular disease, and wide-field fluorescein angiography may provide better visualization," he said.

Fluorescein angiography, he pointed out, is also very effective in, for example, a patient with poor vision and central vein occlusion who was treated with intravitreal triamcinolone. The OCT showed thinning. "In this case, the OCT is not the full story in explaining visual acuity. The preoperative fluorescein angiogram of central retinal vein occlusion showed a suggestion of capillary nonperfusion. In this setting, in which the retinal circulation is involved, fluorescein angiography is indispensable," Dr. Puliafito said.

The management of choroidal neovascularization is an area that is changing rapidly. "I believe that fluorescein angiography should always be used in making the initial diagnosis," he said.

OCT advantages

"However, with the advent of anti-vascular endothelial growth factor (VEGF) therapy, angiographic subtype classification is declining in importance and most treatment decisions can be made using OCT. OCT shows why patients do not see well because of macular edema, subretinal fluid, and pigment epithelial detachment (PED)," he commented.

At Bascom Palmer, Dr. Puliafito and colleagues use visual acuity measurement and OCT for longitudinal follow-up for patients taking anti-VEGF therapy. He provided an example of a patient who appeared to have occult disease, but the OCT revealed retinal angiomatous proliferation. When treated with an anti-VEGF agent, the PED collapsed, but later recurred along with edema. Re-treatment was followed by restoration of the normal anatomy, improved vision, but then recurrence 2 months later. "We use OCT interactively," he said.

"OCT is continuing to develop and improve. We can obtain 30,000 A scans from a scan of a 6-mm box. The technology shows clinically relevant anatomy, it is quantitative, and it will guide retinal pharmacology therapy," Dr. Puliafito said. "At Bascom Palmer, we have a strategy to develop three-dimensional maps that can be used in a realistic way. This technology provides a much more precise story of the clinical picture. The images are perfectly registered and provide precise measurements of the retinal structures. Volume measurements are also available and can be easily obtained; these values can be continually used to monitor the patient's clinical situation. We are going to use these measurements to help make treatment decisions.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.